With antimicrobial resistance rising as one of the world's most pressing health threats, the 8th World Congress on Targeting ...

In the fight against antimicrobial-resistant (AMR) superbugs, an important weapon may just be hiding in some polluted stream, ...

Biomx Inc., a company specializing in phage therapy, presented its first-quarter earnings call for 2025, highlighting significant progress in its clinical trials and strategic initiatives.

This important study analyzes the effect of heat treatment on phage-bacterial interactions and convincingly shows that prior heat exposure alters the bacterial cell envelope, enhancing persistence and ...

BiomX’s acquisition of Adaptive Phage Therapeutics is looking like a good bet now that one of the treatments from the deal ...

BiomX's BX211 virus therapy shows promise in Phase 2 trial, reducing foot ulcer size in diabetic bone infection patients ...

Although the advent and mass production of antibiotics caused a decline in phage therapy, the recent rise in antibiotic resistance has renewed the global interest in this line of treatment. In this ...

In a growing global trend, bacteria are evolving new ways to maneuver around medical treatments for a variety of infections.

Biomx Inc., a company specializing in phage therapy, presented its first-quarter earnings call for 2025, highlighting significant progress in its clinical trials and strategic initiatives. The company ...

Compared to placebo, BX211 also produced statistically significant1 improvements in both ulcer depth at week 13 (in patients with ulcer depth defined as bone at baseline) (p=0.048), and in reducing ...